Dermapharm Holding SE
VerifiedOffers dermatological, skin care, and allergy medicines
Launch date
Employees
Ownership
Market cap
€2.7b
Net debt
€893m
Firm valuation
$4.1b (Public information from 2022)
Share price
€50.01
Hünenberg Canton of Zug (HQ)
Deals in current and previous year:
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 467m | 572m | 701m | 794m | 947m | 1.1b |
| % growth | - | - | 22 % | 23 % | 13 % | 19 % | 15 % |
| EBITDA | - | 113m | 143m | 178m | 201m | 342m | 397m |
| % EBITDA margin | - | 24 % | 25 % | 25 % | 25 % | 36 % | 36 % |
| Profit | - | 20m | 75m | 77m | 85m | 199m | 231m |
| % profit margin | - | 4 % | 13 % | 11 % | 11 % | 21 % | 21 % |
| EV / revenue | - | - | 2.3x | 3.7x | 4.5x | 4.0x | 3.4x |
| EV / EBITDA | - | - | 9.2x | 14.7x | 17.7x | 11.2x | 9.4x |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €328m Valuation: €1.5b | IPO | |
| Total Funding | - | ||
Recent News about Dermapharm Holding SE
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Dermapharm Holding SE
Edit
ACQUISITION by Dermapharm Holding SE Dec 2021